{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:08:03Z","timestamp":1788962883768,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004388","name":"Cephalon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40264-026-01686-2","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:58:00Z","timestamp":1781150280000},"page":"1211-1222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Risk of Adverse Maternal and Infant Outcomes Following Prenatal Modafinil Exposure: A French Nationwide Cohort Study"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3352-8480","authenticated-orcid":false,"given":"Sigal","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"de Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Contini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"1686_CR1","unstructured":"Cephalon Inc. PROVIGIL\u00ae (modafinil) tablets [Prescribing Information]. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020717s037s038lbl.pdf. Accessed 11 Nov 2025."},{"key":"1686_CR2","unstructured":"Cephalon Inc. NUVIGIL\u00ae (armodafinil) tablets [Prescribing Information]. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021875s023lbl.pdf. Accessed 11 Nov 2025."},{"key":"1686_CR3","unstructured":"Teva GmbH. Summary of product characteristics-Vigil\u00ae (modafinil). 2022. https:\/\/mri.cts-mrp.eu\/portal\/details?productnumber=DE\/H\/3259\/001. Accessed 11 Nov 2025."},{"issue":"10","key":"1686_CR4","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.5664\/jcsm.7966","volume":"15","author":"M Pascoe","year":"2019","unstructured":"Pascoe M, Carter LP, Honig E, Bena J, Foldvary-Schaefer N. Pregnancy and contraception experiences in women with narcolepsy: a narcolepsy network survey. J Clin Sleep Med. 2019;15(10):1421\u20136. https:\/\/doi.org\/10.5664\/jcsm.7966.","journal-title":"J Clin Sleep Med"},{"key":"1686_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2025.08.001","author":"GL Dunietz","year":"2025","unstructured":"Dunietz GL, Chervin RD, Tauman R, Shaklai S, Sankari A. OSA in women: associations with reproductive aging and screening challenges. Chest. 2025. https:\/\/doi.org\/10.1016\/j.chest.2025.08.001.","journal-title":"Chest"},{"issue":"2","key":"1686_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamainternmed.2020.4009","volume":"181","author":"S Kaplan","year":"2021","unstructured":"Kaplan S, Braverman DL, Frishman I, Bartov N. Pregnancy and fetal outcomes following exposure to modafinil and armodafinil during pregnancy. JAMA Intern Med. 2021;181(2):275\u20137. https:\/\/doi.org\/10.1001\/jamainternmed.2020.4009.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"1686_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jama.2020.9840","volume":"324","author":"CE Cesta","year":"2020","unstructured":"Cesta CE, Engeland A, Karlsson P, Kieler H, Reutfors J, Furu K. Incidence of malformations after early pregnancy exposure to modafinil in Sweden and Norway. JAMA. 2020;324(9):895\u20137. https:\/\/doi.org\/10.1001\/jama.2020.9840.","journal-title":"JAMA"},{"issue":"4","key":"1686_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jama.2019.20008","volume":"323","author":"P Damkier","year":"2020","unstructured":"Damkier P, Broe A. First-trimester pregnancy exposure to modafinil and risk of congenital malformations. JAMA. 2020;323(4):374\u20136. https:\/\/doi.org\/10.1001\/jama.2019.20008.","journal-title":"JAMA"},{"issue":"5","key":"1686_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/acps.13643","volume":"150","author":"M Onken","year":"2024","unstructured":"Onken M, Lohse L, Coulm B, Beghin D, Richardson JL, Bermejo-S\u00e1nchez E, et al. Effects of maternal modafinil treatment on fetal development and neonatal growth parameters\u2014a multicenter case series of the European Network of Teratology Information Services (ENTIS). Acta Psychiatr Scand. 2024;150(5):372\u201384. https:\/\/doi.org\/10.1111\/acps.13643.","journal-title":"Acta Psychiatr Scand"},{"key":"1686_CR10","unstructured":"European network for surveillance of congenital anomalies (EUROCAT). European surveillance of congenital anomalies (EUROCAT) Guide 1.4 and reference documents. 2018. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/Full_Guide_1_4_version_28_DEC2018.pdf. Accessed 25 Feb 2025."},{"key":"1686_CR11","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2147\/clep.S278596","volume":"12","author":"A Broe","year":"2020","unstructured":"Broe A, Damkier P, Potteg\u00e5rd A, Hallas J, Bliddal M. Congenital malformations in Denmark: considerations for the use of Danish health care registries. Clin Epidemiol. 2020;12:1371\u201380. https:\/\/doi.org\/10.2147\/clep.S278596.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"1686_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pedneo.2014.03.010","volume":"56","author":"A Egbe","year":"2015","unstructured":"Egbe A, Uppu S, Lee S, Stroustrup A, Ho D, Srivastava S. Congenital malformations in the newborn population: a population study and analysis of the effect of sex and prematurity. Pediatr Neonatol. 2015;56(1):25\u201330. https:\/\/doi.org\/10.1016\/j.pedneo.2014.03.010.","journal-title":"Pediatr Neonatol"},{"key":"1686_CR13","unstructured":"EUROCAT. European network for surveillance of congenital anomalies (EUROCAT)\u2014prevalence charts and tables. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/eurocat-data\/prevalence_en. Accessed 23 Feb 2025."},{"issue":"1","key":"1686_CR14","first-page":"1","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","unstructured":"Centers for Disease Control and Prevention. Update on overall prevalence of major birth defects\u2013Atlanta, Georgia, 1978\u20132005. MMWR Morb Mortal Wkly Rep. 2008;57(1):1\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7251","key":"1686_CR15","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1136\/bmj.320.7251.1708","volume":"320","author":"AM Nybo Andersen","year":"2000","unstructured":"Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320(7251):1708\u201312. https:\/\/doi.org\/10.1136\/bmj.320.7251.1708.","journal-title":"BMJ"},{"issue":"11","key":"1686_CR16","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1111\/aogs.13860","volume":"99","author":"\u00d8 Lidegaard","year":"2020","unstructured":"Lidegaard \u00d8, Mikkelsen AP, Egerup P, Kolte AM, Rasmussen SC, Nielsen HS. Pregnancy loss: a 40-year nationwide assessment. Acta Obstet Gynecol Scand. 2020;99(11):1492\u20136. https:\/\/doi.org\/10.1111\/aogs.13860.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"1686_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ppe.12417","volume":"32","author":"LM Rossen","year":"2018","unstructured":"Rossen LM, Ahrens KA, Branum AM. Trends in risk of pregnancy loss among US women, 1990\u20132011. Paediatr Perinat Epidemiol. 2018;32(1):19\u201329. https:\/\/doi.org\/10.1111\/ppe.12417.","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"7","key":"1686_CR18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/pds.4556","volume":"27","author":"PO Bloti\u00e8re","year":"2018","unstructured":"Bloti\u00e8re PO, Weill A, Dalichampt M, Billionnet C, Mezzarobba M, Raguideau F, et al. Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: an application to antiepileptic drug use in 4.9 million pregnant women in France. Pharmacoepidemiol Drug Saf. 2018;27(7):763\u201370. https:\/\/doi.org\/10.1002\/pds.4556.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1686_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/cpj.0000000000200551","volume":"15","author":"S Kaplan","year":"2025","unstructured":"Kaplan S, Carneal-Frazer N, Braverman DL, Parsley L, Robinson C, Benjamin DK, et al. Pregnancy and fetal outcomes following prenatal exposure to modafinil and\/or armodafinil: a 14-year registry study. Neurol Clin Pract. 2025;15(6):e200551. https:\/\/doi.org\/10.1212\/cpj.0000000000200551.","journal-title":"Neurol Clin Pract"},{"key":"1686_CR20","doi-asserted-by":"publisher","unstructured":"Witzleb AJ, Wentzell N, Schink T, Haug U. Abstracts of the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16\u201317, 2020: ICPE All Access conference abstracts. Exploratory analyses of modafinil utilization during pregnancy and diagnoses of malformations in the offspring (#3704). Pharmacoepidemiol Drug Saf. 2020;29(S3):3\u2013634. https:\/\/doi.org\/10.1002\/pds.5114.","DOI":"10.1002\/pds.5114"},{"key":"1686_CR21","doi-asserted-by":"publisher","unstructured":"Callahan C, Lyons JG, Barrett K, Campbell D, Leishear K, Ceresa C, et al. Abstracts of ISPEs 2024, 40th international conference, 24\u201328 August 2024, Germany. Assessment of non-cardiac congenital malformations and in utero exposure to modafinil\/armodafinil in the Sentinel Distributed Database (#150). Pharmacoepidemiol Drug Saf. 2024;33(S2):e5891. https:\/\/doi.org\/10.1002\/pds.5891.","DOI":"10.1002\/pds.5891"},{"key":"1686_CR22","unstructured":"Teva GmbH. Summary of product characteristics: modafinil. 2026. https:\/\/mri-production.cts-mrp.eu\/details?productnumber=DE%2FH%2F3259%2F001. Accessed 16 March 2026."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01686-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:12:06Z","timestamp":1788959526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01686-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1686"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01686-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sigal Kaplan is an employee of Teva Pharmaceutical Industries Ltd. Julie de Nascimento and Andrea Contini are employees of IQVIA, which conducted the study under a contract with Teva.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with French regulations, the study protocol was approved by the ethics and scientific committee for health research, studies, and evaluations (CESREES, study file n\u00b0 5877999) and by the French data privacy committee (CNIL authorization n\u00b0 DR-2021-347). Data access was delivered by CNAM after agreement.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The sponsor had a role in the design and conduct of the study; study supervision, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.","order":5,"name":"Ethics","label":"Role of the Funder\/Sponsor","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The original contributions presented in the analysis are included in this published article and its supplementary information files.","order":6,"name":"Ethics","label":"Availability of Data and Material (Data Transparency)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not available.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SK: study supervision, analysis, interpretation of data, drafting the manuscript. JN: analysis, interpretation of data. AC: study supervision, analysis, interpretation of data. All authors read and critically revised the manuscript for important intellectual content and approved the final version.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this article are those of the authors and do not necessarily reflect those of Cephalon, Inc. and\/or its affiliates (including but not limited to Teva Pharmaceutical Industries Ltd).","order":9,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}]}}